Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from nine to ten directors with Christopher Peetz appointed independent Class III director through the 2029 annual meeting.
Arcutis Biotherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from nine to ten directors with Christopher Peetz appointed independent Class III director through the 2029 annual meeting
- Mirum Pharmaceuticals CEO brings commercial-stage biotechnology and prior M&A experience to Arcutis’s board
- Initial option award covers 21,486 shares, vesting in three equal annual installments
- Prorated annual equity award valued approximately $350,000 and $50,000 prorated cash retainer
- No committee assignment, related-party transaction, family relationship, or selection arrangement disclosed
Item 7.01 · Regulation FD Disclosure
- Press release announces Mr. Peetz’s appointment, signaling a leadership change at Arcutis
- Exhibit 99.1 contains the substantive appointment details and any related transition information
Item EX-99.1 · Exhibit EX-99.1
- Christopher Peetz appointed Arcutis director effective July 15, 2026
- Mirum Pharmaceuticals CEO brings commercialization, pipeline-building, and acquisition expertise
- Appointment supports ZORYVE franchise expansion and external innovation strategy
- ZORYVE spans atopic dermatitis, plaque psoriasis, and seborrheic dermatitis indications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcutis Biotherapeutics, Inc. 8-K filings
Get the next ARQT 8-K as it lands
Follow ARQT for push alerts, or ask the research agent what this filing means.